Business Description
SILO Pharma Inc
NAICS : 541713
SIC : 8731
ISIN : US82711P2011
Total Employee Number:
3Description
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.81 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.19 | |||||
Beneish M-Score | 0.96 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -35.2 | |||||
3-Year EBITDA Growth Rate | 33.7 | |||||
3-Year EPS without NRI Growth Rate | 32.2 | |||||
3-Year FCF Growth Rate | 25.9 | |||||
3-Year Book Growth Rate | -47.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 22.04 | |||||
9-Day RSI | 31.25 | |||||
14-Day RSI | 36.06 | |||||
3-1 Month Momentum % | -7.99 | |||||
6-1 Month Momentum % | 8.92 | |||||
12-1 Month Momentum % | -39.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.65 | |||||
Quick Ratio | 9.65 | |||||
Cash Ratio | 8.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -61.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 11.11 | |||||
Operating Margin % | -6641.67 | |||||
Net Margin % | -6726.39 | |||||
EBITDA Margin % | -6658.33 | |||||
FCF Margin % | -5406.94 | |||||
OCF Margin % | -5337.5 | |||||
ROE % | -93.41 | |||||
ROA % | -72.15 | |||||
ROIC % | -1505.67 | |||||
3-Year ROIIC % | -433.56 | |||||
ROCE % | -82.12 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 38.78 | |||||
PB Ratio | 0.83 | |||||
Price-to-Tangible-Book | 0.86 | |||||
EV-to-EBIT | 0.28 | |||||
EV-to-EBITDA | 0.29 | |||||
EV-to-Revenue | -19.01 | |||||
EV-to-FCF | 0.35 | |||||
Price-to-GF-Value | 0.84 | |||||
| Price-to-Net-Current-Asset-Value | 0.86 | |||||
| Price-to-Net-Cash | 0.95 | |||||
Earnings Yield (Greenblatt) % | 357.14 | |||||
FCF Yield % | -79.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SILO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SILO Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.072 | ||
| EPS (TTM) ($) | -7.443 | ||
| Beta | 1.2394 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.17 | ||
| Volatility % | 56.82 | ||
| 14-Day RSI | 36.06 | ||
| 14-Day ATR ($) | 0.560044 | ||
| 20-Day SMA ($) | 5.45575 | ||
| 12-1 Month Momentum % | -39.52 | ||
| 52-Week Range ($) | 3.314999 - 15.149999 | ||
| Shares Outstanding (Mil) | 1.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SILO Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SILO Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 108 days | ||
| General meeting for 2026 | 2026-08-14 11:00 | In 18 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 16 days | ||
| 0.0666667:1 Stock Split | 2026-06-03 | 5.25 (+2.97%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 5.85 (-1.21%) | ||
| Annual report for 2025 | 2026-03-27 | 5.68 (+2.52%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 6.77 (-5.01%) | ||
| General meeting for 2025 | 2025-10-24 11:00 | 8.37 (-0.43%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 10.11 (+8.67%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 12.22 (-1.81%) |
Show
Entries
SILO Pharma Inc Frequently Asked Questions
What is SILO Pharma Inc(SILO)'s stock price today?
The current price of SILO is $4.35. The 52 week high of SILO is $15.15 and 52 week low is $3.31.
When is next earnings date of SILO Pharma Inc(SILO)?
The next earnings date of SILO Pharma Inc(SILO) is 2026-08-13 Est..
Does SILO Pharma Inc(SILO) pay dividends? If so, how much?
SILO Pharma Inc(SILO) does not pay dividend.
Guru Commentaries on NAS:SILO
No articles.
Press Release
Articles on SILO Pharma Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers